Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8057843 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4ETDP1HTTNPC1 | |
| SCHEMBL8067005 | 0.96 | PDK1 (0.38) | ALDH1A1KDM4ETDP1HTTNPC1 | |
| SCHEMBL5515200 | 0.94 | ALDH1A1 (0.47) | ALDH1A1KDM4ETDP1HTTNPC1 | |
| SCHEMBL7822888 | 0.87 | ALDH1A1 (0.41) | ALDH1A1KDM4ETDP1HTTNPC1 | |
| SCHEMBL7815755 | 0.81 | RECQL (0.40) | ALDH1A1KDM4ETDP1HTTNPC1 | |
| SCHEMBL5515232 | 0.81 | HTT (0.51) | ALDH1A1KDM4ETDP1HTTNPC1 | |
| SCHEMBL8704564 | 0.79 | CYP3A4 (0.43) | ALDH1A1KDM4ETDP1HTTNPC1 | |
| SCHEMBL8704569 | 0.79 | CYP3A4 (0.43) | ALDH1A1KDM4ETDP1HTTNPC1 | |
| SCHEMBL8068471 | 0.79 | ALDH1A1 (0.36) | ALDH1A1KDM4ETDP1HTTNPC1 | |
| SCHEMBL8073573 | 0.78 | PKM (0.46) | ALDH1A1KDM4ETDP1HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238812-B2 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEJI SEIKA KAISHA, LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20060074074-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| US-7022860-B2 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1026167-B1 | TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND ANTIALLERGIC AGENTS | MEIJI SEIKA KAISHA (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-20020137739-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2002-09-26 | — | — | US | disclosed |
| US-6372735-B1 | ANTIHISTAMINES | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| EP-1026167-A1 | TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND ANTIALLERGIC | MEIJI SEIKA KAISHA LTD. (JP) | 2000-08-09 | — | — | EP | disclosed |
| US-6093714-A | AN ANTIALLERGENS FOR TREATMENT AND PREVENTION OF BRONCHIAL ASTHMA, ECZEMA, HIVES, ALLERGIC GASTROINTESTINAL TROUBLES, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS | MEIJI SEIKA KAISHA, LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| EP-0834512-A1 | TRICYCLIC BENZAZEPINE COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 1998-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074074-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | HRH4, CYP2D6, CYP2B6 | ALDH1A1 959/4885KDM4E 752/4885TDP1 1842/4885 |
| US-20020137739-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | HRH4, CYP3A4, TPH1 | ALDH1A1 691/4885KDM4E 547/4885TDP1 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.